MAPLE GROVE, Minn. — Upsher-Smith Laboratories (Upsher-Smith) announced that it will be featuring Platinum Pass, the latest addition to the Access Pathways Program for Qudexy XR (topiramate) extended-release capsules at the 60th Annual Scientific Meeting of the American Headache Society (AHS), June 28 to July 1, in San Francisco, Calif.
The Platinum Pass is designed to eliminate barriers associated with prescribing and provides healthcare professionals with the tools necessary to help their patients Start, Stay and Save on Qudexy XR therapy. Qudexy XR is indicated for use in the prevention of migraine headaches in adults and adolescents 12 years of age and older. Qudexy XR is also indicated to treat certain types of seizures.
- $0 Per Prescription – Regardless of Coverage
- Good for a Maximum of 365 Days of Therapy Over the Next 12 Months – Renewable Annually
- No Activation Required Prior to Going to a Preferred Pharmacy
“We are looking forward to connecting with healthcare professionals at this year’s AHS Annual Scientific Meeting to discuss Upsher-Smith’s newest addition to its savings and support program,” said Rusty Field, president and chief executive officer, Upsher-Smith. “The Platinum Pass makes it easier than ever for physicians to prescribe Qudexy XR for migraine prevention while offering patients a substantial cost savings option.”